Invention Grant
![Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof](/docs/US/2020-08-25/US10752599B2/abs.jpg.600x600.jpg)
- Patent Title: Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
-
Application No.: US16582051Application Date: 2019-09-25
-
Publication No.: US10752599B2Publication Date: 2020-08-25
- Inventor: Adam D. Hughes , Melissa Fleury , Miroslav Rapta , Venkat R. Thalladi , Gene Timothy Fass , Michael Simeone
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Timothy R. Welch
- Main IPC: C07D261/18
- IPC: C07D261/18 ; A61K31/415 ; A61K45/06 ; A61K9/48 ; A61K9/00
![Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof](/abs-image/US/2020/08/25/US10752599B2/abs.jpg.150x150.jpg)
Abstract:
In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I′) forms.
Public/Granted literature
Information query
